Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2012; 18(47): 7079-7086
Published online Dec 21, 2012. doi: 10.3748/wjg.v18.i47.7079
Figure 1
Figure 1 Solid tumors from tumor-bearing mice. ADM: Adriamycin; RFP: Rifampicin; NS: Normal saline; APS: Astragalus polysaccharides; VER: Verapamil.
Figure 2
Figure 2 P-glycoprotein expression in tumor tissues after different chemotherapeutic treatment. A: Normal saline group (No.1-5); B: Adriamycin (ADM) group (No.1-5); C: ADM + rifampicin (RFP) group (No.1-5); D: ADM + astragalus polysaccharides (APS) (50 mg/kg) group (No.1-5); E: ADM + APS (100 mg/kg) group (No.1-5); F: ADM + APS (200 mg/kg) group (No.1-5); G: ADM + verapamil (VER) group (No.1-5); H: NS group (No. 6-10); I: ADM group (No. 6-10); J: ADM + RFP group (No. 6-10); K: ADM + APS (50 mg/kg) group (No. 6-10); L: ADM + APS (100 mg/kg) group (No. 6-10); M: ADM + APS (200 mg/kg) group (No. 6-10); N: ADM + VER group (No. 6-10). P-GP: P-glycoprotein.
Figure 3
Figure 3 P-glycoprotein optical density values and MDR1 mRNA expression in tumor tissues after different chemotherapeutic treatment. A: P-glycoprotein (P-GP) optical density values; B: MDR1 mRNA expression. aP < 0.05 vs adriamycin (ADM) group; cP < 0.05 vs ADM + rifampicin (RFP) group. NS: Normal saline; APS: Astragalus polysaccharides; VER: Verapamil.